Bard Financial Services Inc. Has $10.58 Million Stock Position in Novo Nordisk A/S (NYSE:NVO)

Bard Financial Services Inc. lowered its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 8.5% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 88,890 shares of the company’s stock after selling 8,275 shares during the period. Novo Nordisk A/S makes up 1.2% of Bard Financial Services Inc.’s portfolio, making the stock its 18th biggest position. Bard Financial Services Inc.’s holdings in Novo Nordisk A/S were worth $10,584,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Natixis Advisors LLC lifted its holdings in Novo Nordisk A/S by 2.7% in the 3rd quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock worth $366,125,000 after buying an additional 80,070 shares during the period. Zions Bancorporation N.A. raised its position in shares of Novo Nordisk A/S by 57.0% in the 3rd quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock worth $2,207,000 after acquiring an additional 6,726 shares in the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Novo Nordisk A/S by 14.8% in the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 289,438 shares of the company’s stock worth $34,463,000 after acquiring an additional 37,346 shares in the last quarter. Private Wealth Partners LLC raised its position in shares of Novo Nordisk A/S by 155.1% in the 3rd quarter. Private Wealth Partners LLC now owns 33,203 shares of the company’s stock worth $3,953,000 after acquiring an additional 20,188 shares in the last quarter. Finally, MayTech Global Investments LLC increased its position in Novo Nordisk A/S by 14.1% during the 3rd quarter. MayTech Global Investments LLC now owns 254,552 shares of the company’s stock valued at $30,309,000 after buying an additional 31,475 shares in the last quarter. 11.54% of the stock is owned by institutional investors and hedge funds.

Novo Nordisk A/S Price Performance

NYSE:NVO opened at $110.61 on Wednesday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. The business’s 50-day simple moving average is $111.15 and its two-hundred day simple moving average is $126.90. The stock has a market cap of $496.37 billion, a PE ratio of 35.34, a P/E/G ratio of 1.41 and a beta of 0.40. Novo Nordisk A/S has a 52 week low of $94.96 and a 52 week high of $148.15.

Wall Street Analysts Forecast Growth

A number of research firms recently weighed in on NVO. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. BMO Capital Markets cut their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research note on Thursday, October 17th. StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reiterated an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average price target of $150.40.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.